Swedish Orphan Biovitrum Appoints Mats-Olof Wallin as Interim Chief Financial Officer
Published: Apr 08, 2013
STOCKHOLM, SWEDEN--(Marketwired - April 08, 2013) - Mats-Olof Wallin has been appointed interim Chief Financial Officer at Swedish Orphan Biovitrum AB (Sobi). Wallin - until recently the CFO of Swedish biotech company Biotage AB (publ.) - brings more than 30 years of experience in the pharmaceutical industry, gained from various executive positions within companies such as Pharmacia, Ortivus and Biotage. Wallin has been working at Sobi for the past several months.
"We are glad to welcome Mats-Olof as interim CFO. Mats-Olof brings significant experience to the role and will join our senior team in building a sustainable company which brings value to all stakeholders", said CEO Geoffrey McDonough.
Annika Muskantor, who has been interim CFO since August 2012, will support Mats-Olof in his new role during a transition period.
Continued McDonough: "I would like to thank Annika for her excellent work the past year. She has built a strong financial platform which will continue to support the development of this company."
Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on inflammation and genetic diseases, with three late stage biological development projects within hemophilia and neonatology. We also market a portfolio of specialty and rare disease products for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2012, Sobi had total revenues of SEK 1.9 billion (EUR 215 M) and about 480 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com
Sobi press release April 8, 2013 in pdf version :
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE
For more information - not for
Head of Communications
T: +46 70 410 71 80
Vice President, Head of Investor Relations
T: +46 8 697 20 00